Company: PFSA
Filing Date: 2025-08-11
Form Type: S-1
Source: 0001213900-25-073872
Chunk: 274

Company: Profusa, Inc.
Filing Date: 2025-08-11
Form: S-1
Chunk 274
---
 diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):

|                                                                                |     | Year Ended   
 December 31, 
 2024         |           |   |     | Year Ended   
 December 31, 
 2023         |           |   |
|:-------------------------------------------------------------------------------|:----|:-------------|----------:|:--|:----|:-------------|----------:|:--|
| Numerator:                                                                     |     |              |           |   |     |              |           |   |
| Net loss                                                                       |     | $            |    (9,230 | ) |     | $            |   (10,281 | ) |
| Denominator:                                                                   |     |              |           |   |     |              |           |   |
| Weighted average shares used to computing basic and diluted net loss per share |     |              | 5,604,651 |   |     |              | 5,600,741 |   |
| Net loss per share attributable to common stockholders – basic and diluted:    |     | $            |     (1.65 | ) |     | $            |     (1.84 | ) |

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

|                                  |     |  Years ended 
 December 31, |      |     |            |      |
|                                  |     |         2024 |      |     |       2023 |      |
| Convertible preferred stock      |     |   17,863,934 |      |     | 17,863,934 |      |
| Convertible notes payable        |     |    3,363,624 |      |     |  2,251,941 | ​(1) |
| Convertible loans                |     |            — | ​(2) |     |          — |      |
| Options to purchase common stock |     |    2,972,055 |      |     |  2,982,055 |      |
| Total                            |     |   24,199,613 |      |     | 23,097,930 |      |

____________

(1)

(2)

Note 12 — Government Grant Revenue Government grant revenue consists of amounts the Company earns under grants from two government agencies: NIH and DAR